July 16, 2013
Astellas Pharma announced on July 11 that it has launched its oral androgen receptor signaling inhibitor Xtandi (enzalutamide) in the UK. Xtandi was approved in Europe in June this year for the treatment of adult men with metastatic castration-resistant prostate...read more